TiGenix: Transparency Information
July 02 2018 - 4:00PM
PRESS RELEASE
REGULATED INFORMATION
Transparency
Information
Leuven (Belgium)
- July 2, 2018, 22:00h CET - TiGenix NV (Euronext Brussels and
Nasdaq: TIG) publishes information in accordance with articles
15 and 18 of the Belgian Law of May 2, 2007 regarding the
publication of major holdings in issuers whose securities are
admitted to trading on a regulated market and including various
provisions (the Law) and the Royal Decree of
February 14, 2008 regarding the publication of major
holdings.
Following the issuance of
11,905,171 new shares on July 2, 2018 resulting from the exercise
of 11,905,171 warrants of TiGenix NV, the transparency data have
changed as follows (status on July 2, 2018):
· Information to be published in accordance with Article 15,
§1, al. 1 of the Law
Total of
the registered capital: |
EUR
30,882,907.70 |
Total
number of securities conferring voting rights: |
307,973,027 |
Total
number of voting rights (denominator): |
307,973,027 |
· Information to be published in accordance with Article 15,
§1, al. 2 of the Law
Total number of rights
(materialized or not in financial instruments) to subscribe for yet
unissued financial instruments that are treated as securities
conferring voting rights: 585,443 granted and outstanding warrants
which, in case they are all exercised, give rise to a total number
of 585,443 voting rights.
TiGenix NV has not issued any
other rights to subscribe to securities conferring voting rights or
any securities without voting rights.
· Information to be published in accordance with Article 18,
§1 of the Law
Each physical or legal person
acquiring or transferring TiGenix NV's shares is required to notify
the Belgian Financial Services and Markets Authority (FSMA) and
TiGenix NV each time their shareholding crosses a threshold of
three percent (3%) of the total number of voting securities (the
denominator) (upwards or downwards). Such notification is also
required when the threshold of five percent (5%) or a multiple of
five percent (5%) is crossed.
Complete information regarding
this requirement can be found in Article 14 of the articles of
association of TiGenix NV.
Notifications must be submitted to
both the FSMA and TiGenix NV.
To the FSMA:
-
by e-mail: trp.fin@fsma.be, and
-
a signed copy (for reasons of legal
certainty) by fax: +32 2 220 59 12
A copy of the notification must also be sent to
TiGenix NV for the attention of Claudia Jiménez, Senior Director
Investor Relations and Communications:
-
by e-mail: investor@tigenix.com,
and
-
a signed copy (for reasons of legal
certainty) by fax: +32 16 39 79 70
For submitting the notifications,
the FSMA recommends to use its standard form TR-1BE that is
available on the FSMA website (https://www.fsma.be/en/node/7121) or
can be requested by e-mail with TiGenix NV:
investor@tigenix.com.
Detailed information regarding the
transparency legislation can be found on the website of the
FSMA.
For more
information
TiGenix
Claudia Jiménez
Senior Director Investor Relations and Communications
Tel: +34918049264
claudia.jimenez@tigenix.com
About TiGenix
TiGenix NV
(Euronext Brussels and NASDAQ: TIG) is an advanced
biopharmaceutical company developing novel therapies for serious
medical conditions by exploiting the anti-inflammatory properties
of allogeneic, or donor-derived, stem cells.
TiGenix lead
product, Alofisel (darvadstrocel), previously Cx601, received
European Commission (EC) approval for the treatment of complex
perianal fistulas in adult patients with non-active/mildly active
luminal Crohn's disease, when fistulas have shown an inadequate
response to at least one conventional or biologic therapy. A global
Phase III trial intended to support a future U.S. Biologic License
Application (BLA) started in 2017. TiGenix has entered into a
licensing agreement with Takeda, a global pharmaceutical company
active in gastroenterology, under which Takeda acquired the
exclusive right to develop and commercialize Alofisel for complex
perianal fistulas outside the U.S. TiGenix' second adipose-derived
product, Cx611, is undergoing a Phase I/II trial in severe sepsis -
a major cause of mortality in the developed world. TiGenix is
headquartered in Leuven (Belgium) and has operations in Madrid
(Spain) and Cambridge, MA (USA). For more information, please visit
http://www.tigenix.com.
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: TiGenix via Globenewswire
Trean Insurance (NASDAQ:TIG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Trean Insurance (NASDAQ:TIG)
Historical Stock Chart
From Jul 2023 to Jul 2024